Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aquinox Pharmaceutic (AQXP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 367,696
  • Shares Outstanding, K 23,510
  • Annual Sales, $ 0 K
  • Annual Income, $ -50,180 K
  • 36-Month Beta -14.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.25 +20.16%
on 05/23/18
16.14 -8.80%
on 06/18/18
+2.21 (+17.67%)
since 05/21/18
3-Month
12.00 +22.67%
on 05/01/18
16.47 -10.63%
on 03/23/18
+0.28 (+1.94%)
since 03/21/18
52-Week
10.02 +46.91%
on 12/12/17
16.90 -12.90%
on 02/14/18
+0.04 (+0.27%)
since 06/21/17

Most Recent Stories

More News
Innovative Biotech Companies, Preparing for the Future

LAS VEGAS, NV / ACCESSWIRE / June 15, 2018 / Some innovative biotechnology companies that are working on ground-breaking technology and are prepared for the future include: Propanc Biopharma, Inc. (OTCQB:...

CLDX : 0.56 (-3.97%)
PPCHD : 1.2000 (+20.00%)
AQXP : 14.72 (-5.88%)
PPCB : 0.0619 (-3.28%)
CPRX : 3.18 (-6.47%)
Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS

- Trial Will Enroll Approximately 100 Male Subjects in the US and Canada -

AQXP : 14.72 (-5.88%)
Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

-Aquinox to Receive $25M in Upfront Payment, Potentially Over $100M in Additional Milestone Payments and Royalties-

AQXP : 14.72 (-5.88%)
Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 14.72 (-5.88%)
Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 14.72 (-5.88%)
DB : 10.89 (-1.71%)
Aquinox to Present at 2018 Bloom Burton & Co. Healthcare Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 14.72 (-5.88%)
Aquinox to Present at the 17th Annual Needham Healthcare Conference

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 14.72 (-5.88%)
Aquinox Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern...

AQXP : 14.72 (-5.88%)
Aquinox Pharmaceuticals to Announce Year End 2017 Financial Results

Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers,...

AQXP : 14.72 (-5.88%)
Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor

--Enrollment target reached; topline data

AQXP : 14.72 (-5.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade AQXP with:

Business Summary

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.

See More

Key Turning Points

2nd Resistance Point 16.34
1st Resistance Point 15.53
Last Price 14.72
1st Support Level 14.17
2nd Support Level 13.62

See More

52-Week High 16.90
Last Price 14.72
Fibonacci 61.8% 14.27
Fibonacci 50% 13.46
Fibonacci 38.2% 12.65
52-Week Low 10.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar